The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients ...

The following is a summary of “Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Bladder cancer is not the only cancer affected by the rule. Patients diagnosed with pancreatic, skin and thyroid cancers could lose access to genetic testing.

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare ...

Anktiva (nogapendekin alfa inbakicep, or N-803) can be used in combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients who had not responded to the BCG shot on its ...

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).